Wall Street brokerages predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report sales of $73.64 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings. The highest sales estimate is $76.25 million and the lowest is $70.86 million. Collegium Pharmaceutical posted sales of $10.79 million during the same quarter last year, which would indicate a positive year over year growth rate of 582.5%. The company is scheduled to report its next earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year sales of $280.30 million for the current fiscal year, with estimates ranging from $277.85 million to $283.24 million. For the next financial year, analysts anticipate that the firm will post sales of $310.43 million, with estimates ranging from $310.00 million to $311.16 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). The business had revenue of $70.20 million for the quarter, compared to analysts’ expectations of $74.79 million. Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The company’s revenue was up 485.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.45) EPS.

COLL has been the subject of several recent research reports. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Friday, November 30th. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 13th. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price target (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday, January 16th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $30.14.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $15.56, for a total transaction of $389,000.00. Following the sale, the director now owns 286,000 shares in the company, valued at $4,450,160. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 75,000 shares of company stock worth $1,258,500. Company insiders own 13.87% of the company’s stock.

Several large investors have recently bought and sold shares of COLL. Meeder Asset Management Inc. grew its stake in shares of Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after purchasing an additional 3,179 shares during the last quarter. Vanguard Group Inc lifted its holdings in Collegium Pharmaceutical by 9.0% in the third quarter. Vanguard Group Inc now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after buying an additional 113,038 shares during the period. Vanguard Group Inc. lifted its holdings in Collegium Pharmaceutical by 9.0% in the third quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after buying an additional 113,038 shares during the period. Morgan Stanley lifted its holdings in Collegium Pharmaceutical by 20.1% in the third quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock worth $15,566,000 after buying an additional 176,577 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in Collegium Pharmaceutical by 6.2% in the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after buying an additional 4,484 shares during the period.

Shares of NASDAQ COLL traded down $0.24 during trading hours on Friday, hitting $15.08. The stock had a trading volume of 15,617 shares, compared to its average volume of 421,372. The stock has a market cap of $523.98 million, a price-to-earnings ratio of -6.11 and a beta of 0.52. Collegium Pharmaceutical has a 52 week low of $13.70 and a 52 week high of $29.90. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.75 and a current ratio of 0.78.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

See Also: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.